Advanced in Acute Myelomonocytic Leukemia

Dr. Dale L. Bixby

Regents Of The University Of Michigan
Ann Arbor, MI
Advanced
in Acute Myelomonocytic Leukemia
Specialties:Hematology | Oncology | Hematology Oncology
Accepting New Patients
OverviewInsuranceLocationsClinical Research

Overview

Dale Bixby is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Bixby and is rated as an Advanced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Bixby is currently accepting new patients.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Hematology Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
University Of Michigan Health System
Covenant Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Priority Health
  •  Blue Cross Blue Shield
  •  McLaren Health

Locations

REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr Dr, Ann Arbor, MI 48109
734-936-5738
Other Locations
REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr, Suite 0331, Ann Arbor, MI 48109
734-936-5738

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: Cytarabine
Study Phase: Phase 2
A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: December 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Enrollment Status: Completed
Publish Date: October 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

92 Total Publications

Impact of Chemotherapy Educational Videos for Patients with Acute Myeloid Leukemia.
Impact of Chemotherapy Educational Videos for Patients with Acute Myeloid Leukemia.
Journal: Journal of cancer education : the official journal of the American Association for Cancer Education
Published: June 20, 2024
Similar Doctors
Expertise in
25
conditions
Dr. Joseph P. Uberti
Hematology Oncology | Oncology | Hematology
Expertise in
25
conditions
Dr. Joseph P. Uberti
Hematology Oncology | Oncology | Hematology

University Physician Group

4100 John R St, 
Detroit, MI 
 (34.7 mi)
800-527-6266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Uberti is a Hematologist Oncology specialist and an Oncologist in Detroit, Michigan. Dr. Uberti and is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Graft Versus Host Disease (GvHD), Multiple Myeloma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant. Dr. Uberti is currently accepting new patients.

Expertise in
38
conditions
Dr. Abhinav K. Deol
Hematology Oncology | Hematology | Oncology
Expertise in
38
conditions
Dr. Abhinav K. Deol
Hematology Oncology | Hematology | Oncology

Barbara Ann Karmanos Cancer Institute

4100 John R St, 
Detroit, MI 
 (34.7 mi)
800-527-6266
Languages Spoken:
English, Punjabi
See accepted insurances
Accepting New Patients

Abhinav Deol is a Hematologist Oncology specialist and a Hematologist in Detroit, Michigan. Dr. Deol and is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Deol is currently accepting new patients.

Expertise in
65
conditions
Dr. Daniel J. Lebovic
Hematology Oncology | Oncology | Hematology
Expertise in
65
conditions
Dr. Daniel J. Lebovic
Hematology Oncology | Oncology | Hematology

Ascension St John Hospital

19229 Mack Ave, Suite 24, 
Grosse Pointe Woods, MI 
 (42.8 mi)
313-884-5522
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Lebovic is a Hematologist Oncology specialist and an Oncologist in Grosse Pointe Woods, Michigan. Dr. Lebovic and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Polycythemia Vera, Bone Marrow Aspiration, and Endoscopy. Dr. Lebovic is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile